High P/S ratio may indicate future outperformance, but poor growth rate suggests these prices may not be sustainable. Continuation of recent medium-term revenue trends could risk shareholders' investments, with potential investors possibly paying excessive premium.

Despite falling prices and revenue, Shenzhen Bioeasy Biotechnology's high P/S ratio indicates investor optimism. However, if expectations aren't met, the stock may be overpriced. The company's recent revenue decline is concerning, especially compared to the industry's expected 26% growth. The high P/S ratio may not be sustainable if these trends continue.